Beyond JAK-2: potential targets for myeloproliferative neoplasm therapy

References

• Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391–2405.
   PubMed Web of Science ®Google Scholar
• Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365:1054–1061.
   PubMed Web of Science ®Google Scholar
• James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434:1144–1148.
   PubMed Web of Science ®Google Scholar
• Pikman Y, Lee BH, Mercher T, et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med. 2006;3:270.
   PubMed Web of Science ®Google Scholar
• Alvarez-Larran A, Pereira A, Guglielmelli P, et al. Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation. Haematologica. 2016;101:926–931.
   PubMed Web of Science ®Google Scholar
• Vannucchi AM, Lasho TL, Guglielmelli P, et al. Mutations and prognosis in primary myelofibrosis. Leukemia. 2013;27:1861–1869.
   PubMed Web of Science ®Google Scholar
• Tefferi A, Guglielmelli P, Larson DR, et al. Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood. 2014;124:2507–2513; quiz 2615.
   Web of Science ®Google Scholar
• Milosevic Feenstra JD, Nivarthi H, Gisslinger H, et al. Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms. Blood. 2016;127:325–332.
   PubMed Web of Science ®Google Scholar
• Cabagnols X, Favale F, Pasquier F, et al. Presence of atypical thrombopoietin receptor [MPL] mutations in triple-negative essential thrombocythemia patients. Blood. 2016;127:333–342.
   PubMed Web of Science ®Google Scholar
• Elala Y, Gangat N, Finke C, et al. 1599 driver mutations and prognosis in 502 patients with essential thrombocythemia. American society of haematology - Poster Presentation. December 2015, Orlando, FL.
   Google Scholar
• Tefferi A, Guglielmelli P, Finke C, et al. Targeted deep sequencing in polycythemia vera and essential thrombocythemia. Blood Adv. 2016;1:21–30.
   PubMed Web of Science ®Google Scholar
• Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012;366:799–807.
   PubMed Web of Science ®Google Scholar
• Harrison C, Kiladjian JJ, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012;366:787–798.
   PubMed Web of Science ®Google Scholar
• Harrison CN, Vannucchi AM, Kiladjian JJ, et al. Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis. Leukemia. 2016;30:1701–1707.
   PubMed Web of Science ®Google Scholar
• Vannucchi AM, Kiladjian JJ, Griesshammer M, et al. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med. 2015;372:426–435.
   PubMed Web of Science ®Google Scholar
• Passamonti F, Saydam G, Lim L, et al. RESPONSE 2: A phase 3b study evaluating the efficacy and safety of ruxolitinib in patients with hydroxyurea - resistant/intolerant polycytheinia vera versus best available therapy. J Clin Oncol. 2014;32:15.
   Web of Science ®Google Scholar
• Harrison CN, Mead A, Panchal A, et al. Ruxolitinib compared with best available therapy for essential thrombocythaemia patients resistant or intolerant to hydroxycarbamide in MAJIC – an investigator lead randomised trial. Poster Presenntation. June 2016. EHA Annual Meeting Abstracts. Copenhagen, Denmark.
   Google Scholar
• Mesa RA, Vannucchi AM, Mead A, et al. Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1]: an international, randomised, phase 3 trial. Lancet Haematol. 2017;4:225–236.
   PubMed Web of Science ®Google Scholar
• Mascarenhas J, Talpaz M, Gerds AT, et al. Results of the persist-2 phase 3 study of pacritinib versus best available therapy, including ruxolitinib, in patients with myelofibrosis and platelet counts <100,000/µl. Blood. 2016;128:LBA–5.
   Google Scholar
• BioPharma C. CTI BioPharma provides update on clinical hold of investigational agent pacritinib and new drug application in U.S. Seattle (WA). Available from: http://investors.ctibiopharma.com/phoenix.zhtml
   Google Scholar
• Asshoff M, Petzer V, Warr MR, et al. Momelotinib inhibits ACVR1/ALK2, decreases hepcidin production, and ameliorates anemia of chronic disease in rodents. Blood. 2017;129:1823–1830.
   PubMed Web of Science ®Google Scholar
• Mesa RA, Kiladjian JJ, Catalano JV, et al. SIMPLIFY-1: a phase III randomized trial of momelotinib versus ruxolitinib in janus kinase inhibitor-naive patients with myelofibrosis. J Clin Oncol. 2017;35:3844–3850.
   PubMed Web of Science ®Google Scholar
• Harrison CN, Platzbecker U, Cervantes F, et al. Phase 3 randomized trial of momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib. J Clin Oncol. 2017;35:7001.
   Web of Science ®Google Scholar
• Zhou T, Georgeon S, Moser R. Specificity and mechanism-of-action of the JAK2 tyrosine kinase inhibitors ruxolitinib and SAR302503 (TG101348). Leukemia. 2014;28:404–407.
   PubMed Web of Science ®Google Scholar
• Harrison CN, Schaap N, Vannucchi AM, et al. Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study. Lancet Haematol. 2017;4:317–324.
   PubMed Web of Science ®Google Scholar
• Pardanani A, Harrison C, Cortes JE, et al. Safety and efficacy of fedratinib in patients with primary or secondary myelofibrosis: a randomized clinical trial. JAMA Oncol. 2015;1:643–651.
   PubMed Web of Science ®Google Scholar
• Harrison CN, R Mesa, Jamieson C, et al. Case series of potential wernicke’s encephalopathy in patients treated with Fedratinib American society of haematology - oral and poster Abstracts. December 2017. Atlanta, Georgia.
   Google Scholar
• Verstovsek S, Talpaz M, Ritchie E, et al. A phase I, open-label, dose-escalation, multicenter study of the JAK2 inhibitor NS-018 in patients with myelofibrosis. Leukemia. 2017;31:393–402.
   PubMed Web of Science ®Google Scholar
• Nakaya Y, Shide K, Niwa T, et al. Efficacy of NS-018, a potent and selective JAK2/Src inhibitor, in primary cells and mouse models of myeloproliferative neoplasms. Blood Cancer J. 2011;1:29.
   PubMed Web of Science ®Google Scholar
• Mascarenhas JO, Talpaz M, Gupta V, et al. Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis. Haematologica. 2017;102:327–335.
   PubMed Web of Science ®Google Scholar
• Mesa RA, Yao X, Cripe LD, et al. Lenalidomide and prednisone for myelofibrosis: Eastern Cooperative Oncology Group (ECOG) phase 2 trial E4903. Blood. 2010;116:4436–4438.
   PubMed Web of Science ®Google Scholar
• Mesa RA, Steensma DP, Pardanani A, et al. A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia. Blood. 2003;101:2534–2541.
   PubMed Web of Science ®Google Scholar
• Daver N, Cortes J, Newberry K, et al. Ruxolitinib in combination with lenalidomide as therapy for patients with myelofibrosis. Haematologica. 2015;100:1058–1063.
   PubMed Web of Science ®Google Scholar
• Tefferi A, Al-Ali HK, Barosi G, et al. A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence. Leukemia. 2017;31:896–902.
   PubMed Web of Science ®Google Scholar
• Stegelmann F, Bangerter M. Ruxolitinib plus pomalidomide in myelofibrosis: updated results from the Mpnsg-0212 trial. Blood. 2016;128:1939.
   Web of Science ®Google Scholar
• Wang Y, Fiskus W, Chong DG, et al. Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells. Blood. 2009;114:5024–5033.
   PubMed Web of Science ®Google Scholar
• Harrison CN, Heidel FH, Vannucchi AM. Efficacy, safety, and confirmation of the recommended phase 2 starting dose of the combination of ruxolitinib and panobinostat in patients with myelofibrosis. Blood. 2015;126:4060.
   Web of Science ®Google Scholar
• Rambaldi A, Iurlo A, Vannucchi A, et al. A two-part study of givinostat in patients with polycythemia vera: maximum tolerated dose definition and preliminary efficacy results. American society of haematology - oral and poster abstracts. December 2017. Atlanta, Georgia.
   Google Scholar
• Fiskus W, Verstovsek S, Manshouri T, et al. Heat shock protein 90 inhibitor is synergistic with JAK2 inhibitor and overcomes resistance to JAK2-TKI in human myeloproliferative neoplasm cells. Clin Cancer Res. 2011;17:7347–7358.
   PubMed Web of Science ®Google Scholar
• Daver N, Pemmaraju N, Jabbour EJ, et al. Ruxolitinib in combination with 5-azacytidine as therapy for patients with myelofibrosis. Blood. 2016;128:1127.
   Web of Science ®Google Scholar
• Liu F, Zhao X, Perna F, et al. JAK2V617F-mediated phosphorylation of PRMT5 downregulates its methyltransferase activity and promotes myeloproliferation. Cancer Cell. 2011;19:283–294.
   PubMed Web of Science ®Google Scholar
• Iancu-Rubin C, Mosoyan G, Wang J, et al. Stromal cell-mediated inhibition of erythropoiesis can be attenuated by Sotatercept (ACE-011), an activin receptor type II ligand trap. Expl Hematol. 2013;41:155–166.
   PubMed Web of Science ®Google Scholar
• Carrancio S, Markovics J, Wong P, et al. An activin receptor IIA ligand trap promotes erythropoiesis resulting in a rapid induction of red blood cells and haemoglobin. Br J Haematol. 2014;165:870–882.
   PubMed Web of Science ®Google Scholar
• Bose P, Jabbour EJ, Pike A, et al. Phase-2 study of sotatercept [ACE-011] in myeloproliferative neoplasm-associated myelofibrosis and anemia. Blood. 2016;128:478.
   Web of Science ®Google Scholar
• Bose P, Pemmaraju N, Jabbour EJ, et al. Sotatercept [ACE-011] alone and in combination with ruxolitinib in patients with myeloproliferative neoplasm-associated myelofibrosis and Anemia. American society of haematology - oral and poster abstracts. December 2017. Atlanta, Georgia.
   Google Scholar
• Hastie ND, Dempster M, Dunlop MG, et al. Telomere reduction in human colorectal carcinoma and with ageing. Nature. 1990;346:866–868.
   PubMed Web of Science ®Google Scholar
• Aalbers AM, Calado RT, Young NS, et al. Telomere length and telomerase complex mutations in pediatric acute myeloid leukemia. Leukemia. 2013;27:1786–1789.
   PubMed Web of Science ®Google Scholar
• Lansdorp PM. Telomeres, stem cells, and hematology. Blood. 2008;111:1759–1766.
   PubMed Web of Science ®Google Scholar
• Spanoudakis E, Bazdiara I, Pantelidou D, et al. Dynamics of telomere’s length and telomerase activity in Philadelphia chromosome negative myeloproliferative neoplasms. Leuk Res. 2011;35:459–464.
   PubMed Web of Science ®Google Scholar
• Baerlocher GM, Oppliger Leibundgut E, Ottmann OG, et al. Telomerase inhibitor imetelstat in patients with essential thrombocythemia. N Engl J Med. 2015;373:920–928.
   PubMed Web of Science ®Google Scholar
• Tefferi A, Lasho TL, Begna KH, et al. A pilot study of the telomerase inhibitor imetelstat for myelofibrosis. N Engl J Med. 2015;373:908–919.
   PubMed Web of Science ®Google Scholar
• Geron announces completion of second internal data reviews for imetelstat trials being conducted by Janssen. Geron Corporation. (press release) cited 2017 June 7.
   Google Scholar
• Groopman JE. The pathogenesis of myelofibrosis in myeloproliferative disorders. Ann Intern Med. 1980;92:857–858.
   PubMed Web of Science ®Google Scholar
• Verstovsek S, Manshouri T, Pilling D, et al. Role of neoplastic monocyte-derived fibrocytes in primary myelofibrosis. J Exp Med. 2016;213:1723–1740.
   PubMed Web of Science ®Google Scholar
• Zahr AA, Salama ME, Carreau N, et al. Bone marrow fibrosis in myelofibrosis: pathogenesis, prognosis and targeted strategies. Haematologica. 2016;101:660–671.
   PubMed Web of Science ®Google Scholar
• Murray LA, Kramer MS, Hesson DP, et al. Serum amyloid P ameliorates radiation-induced oral mucositis and fibrosis. Fibrogenesis Tissue Repair. 2010;3:11.
   PubMedGoogle Scholar
• Murray LA, Rosada R, Moreira AP, et al. Serum amyloid P therapeutically attenuates murine bleomycin-induced pulmonary fibrosis via its effects on macrophages. PLoS One. 2010;5:9683.
   PubMed Web of Science ®Google Scholar
• Verstovsek S, Foltz LM, Gupta V, et al. Phase 2 trial of PRM-151, an anti-fibrotic agent, in patients with myelofibrosis: stage 1 results. Blood. 2014;124:713.
   Google Scholar
• Verstovsek S, Foltz LM, Gupta V, et al. PRM-151 in myelofibrosis: durable efficacy and safety at 72 weeks. Blood. 2015;126:56.
   Web of Science ®Google Scholar
• Mesa RA, Tefferi A, Elliott MA, et al. A phase II trial of pirfenidone (5-methyl-1-phenyl-2-[1H]-pyridone), a novel anti-fibrosing agent, in myelofibrosis with myeloid metaplasia. Br J Hematol. 2001;114:111–113.
   PubMed Web of Science ®Google Scholar
• Wilkins BS, Radia D, Woodley C, et al. Resolution of bone marrow fibrosis in a patient receiving JAK1/JAK2 inhibitor treatment with ruxolitinib. Haematologica. 2013;98:1872–1876.
   PubMed Web of Science ®Google Scholar
• Lekovic D, Gotic M, Perunicic-Jovanovic M, et al. Contribution of comorbidities and grade of bone marrow fibrosis to the prognosis of survival in patients with primary myelofibrosis. Med Oncol. 2014;31:869.
   PubMed Web of Science ®Google Scholar
• Roberts AW, Seymour JF, Brown JR, et al. Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. J Clin Oncol. 2012;30:488–496.
   PubMed Web of Science ®Google Scholar
• Waibel M, Solomon VS, Knight DA, et al. Combined targeting of JAK2 and Bcl-2/Bcl-xL to cure mutant JAK2-driven malignancies and overcome acquired resistance to JAK2 inhibitors. Cell Rep. 2013;5:1047–1059.
   PubMed Web of Science ®Google Scholar
• Will B, Siddiqi T, Jorda MA, et al. Apoptosis induced by JAK2 inhibition is mediated by Bim and enhanced by the BH3 mimetic ABT-737 in JAK2 mutant human erythroid cells. Blood. 2010;115:2901–2909.
   PubMed Web of Science ®Google Scholar
• Lu M, Wang J, Li Y, et al. Treatment with the Bcl-xL inhibitor ABT-737 in combination with interferon alpha specifically targets JAK2V617F-positive polycythemia vera hematopoietic progenitor cells. Blood. 2010;116:4284–4287.
   PubMed Web of Science ®Google Scholar
• Klein C, Zwick A, Kissel S, et al. Ptch2 loss drives myeloproliferation and myeloproliferative neoplasm progression. J Exp Med. 2016;213:273–290.
   PubMed Web of Science ®Google Scholar
• McGowan SE, McCoy DM. Platelet-derived growth factor-A and sonic hedgehog signaling direct lung fibroblast precursors during alveolar septal formation. Am J Physiol Lung Cell Mmol Physiol. 2013;305:229–239.
   PubMed Web of Science ®Google Scholar
• Greenbaum LE. Hedgehog signaling in biliary fibrosis. J Clin Invest. 2008;118:3263–3265.
   PubMed Web of Science ®Google Scholar
• Bhagwat N, Rampal R, Koppikar P, et al. Improved efficacy of combination of JAK2 and hedgehog inhibitors in myelofibrosis. Blood. 2013;122:666.
   PubMed Web of Science ®Google Scholar
• Sasaki K, Gotlib JR, Mesa RA, et al. Phase II evaluation of IPI-926, an oral Hedgehog inhibitor, in patients with myelofibrosis. Leuk Lymphoma. 2015;56:2092–2097.
   PubMed Web of Science ®Google Scholar
• Couban S, Donnellan W. Phase 1b results of a study to assess the efficacy and safety of vismodegib in combination with ruxolitinib in patients with intermediate- or high-risk myelofibrosis. American society of haematol poster abstract. December 2017. Atlanta, Georgia.
   Google Scholar
• Gupta V, Harrison CN, Hasselbalch H, et al. Phase 1b/2 study of the efficacy and safety of Sonidegib [LDE225] in combination with ruxolitinib (INC424) in patients with myelofibrosis. Blood. 2015;126:825.
   PubMed Web of Science ®Google Scholar
• Cervantes F, Pereira A. Does ruxolitinib prolong the survival of patients with myelofibrosis? Blood. 2017;129:832–837.
   PubMed Web of Science ®Google Scholar
• Wolanskyj AP, Schwager SM, McClure RF, et al. Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors. Mayo Clin Proc. 2006;81:159–166.
   PubMed Web of Science ®Google Scholar
• Tefferi A, Rumi E, Finazzi G, et al. Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia. 2013;27:1874–1881.
   PubMed Web of Science ®Google Scholar